CLIN.L - Clinigen Group plc

LSE - LSE Delayed Price. Currency in GBp
-5.00 (-0.61%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close825.00
Bid822.00 x 0
Ask823.00 x 0
Day's Range811.50 - 830.00
52 Week Range716.00 - 1,069.00
Avg. Volume259,544
Market Cap1.086B
Beta (3Y Monthly)0.62
PE Ratio (TTM)205.00
Earnings DateN/A
Forward Dividend & Yield0.07 (0.81%)
Ex-Dividend Date2019-03-21
1y Target EstN/A
Press Releases
  • Business Wire

    Clinigen Appoints James Meyer as General Manager of Commercial Medicines in the US

    Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed James (‘Jim’) Meyer as General Manager, Commercial Medicines, US, with immediate effect. Jim Meyer is an accomplished and seasoned executive with nearly 40 years of experience in the pharmaceutical industry, of which included five years at Teva Pharmaceuticals where he led the Oncology New Products Division in the US. As the Oncology Lead, he was responsible for the commercial development and launch of multiple oncology products.

  • Business Wire

    Clinigen’s Foscavir® gains approval for HHV-6 encephalitis in Japan

    Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that Foscavir (foscarnet sodium) has received approval for the treatment of HHV-6 encephalitis from the Ministry of Health, Labour and Welfare (‘MHLW’) in Japan. Approval of the new indication by the MHLW follows reimbursement received in November 2018. Foscavir is the first medicine in the world to receive approval from a Regulatory Authority for the treatment of HHV-6 encephalitis.

  • Business Wire

    Clinigen and Eiger BioPharmaceuticals Launch Worldwide Managed Access Program for Lonafarnib for Patients with Progeria and Progeroid Laminopathies

    Clinigen Group plc (AIM:CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies. Progeria, also known as Hutchinson-Gilford Progeria Syndrome, is a rare and fatal genetic condition of accelerated aging in children that researchers believe is caused by a genetic mutation that results in an overabundance of the farnesylated aberrant protein named progerin.